Skip to main content
. 2020 Jul 9;10(18):8400–8414. doi: 10.7150/thno.45124

Figure 2.

Figure 2

ERO1L is overexpressed in PDAC and predicts a poor prognosis. (A) Immunohistochemical detection of ERO1L protein expression in normal pancreas from control mice, precursor lesions from Pdx1-Cre; LSL-KrasG12D/+ (KC) mice, and tumor lesions from Pdx1-Cre; LSL-KrasG12D/+; LSL-Trp53R172H/+ (KPC) mice. HE staining was performed to show the representative images of different stages of PanIN lesions; Scale bar: 50 µm. (B) The expression pattern of ERO1L in five independent PDAC cohorts. Data were derived from the GEO database. (C) Representative images of ERO1L protein expression in a tissue microarray containing 205 pathologist-certified and clinically annotated PDAC specimens from Ren Ji cohort; Scale bar: 50 µm. (D) The number of tissue specimens displaying high or low ERO1L staining in paracancerous pancreas and PDAC lesions (Fisher's exact test, **P < 0.01). (E) Kaplan-Meier analysis of the overall survival of PDAC patients based on ERO1L protein expression in Ren Ji cohort (log-rank test, P = 0.0078). (F) Multivariate Cox regression analyses were performed to identify independent prognostic factors for PDAC survival. All the bars correspond to 95% confidence intervals.